

# Access vessels challenges and best access route

**Francesco Setacci**  
"P.Valdoni" Department of Surgery  
Sapienza University of Rome – Rome, Italy

## Disclosure

Speaker name:

**Francesco Setacci**



I have the following potential conflicts of interest to report:

- Consulting for Trivascular
- Employment in industry
- Shareholder in a healthcare company
- Owner of a healthcare company
- Other(s)
  
- I do not have any potential conflict of interest

# Background

MEET 2015  
MULTIDISCIPLINARY EUROPEAN  
ENDOVASCULAR THERAPY

At the beginning of the  
endovascular era  
TEVAR was **only for**  
**selected cases**



# Background


The evolution of devices and imaging allows us to think about treating more complex cases



# Background



1987



2002




2012




# Background

**MEET** 2015  
MULTIDISCIPLINARY EUROPEAN  
ENDOVASCULAR THERAPY



# Background

**MEET** 2015  
MULTIDISCIPLINARY EUROPEAN  
ENDOVASCULAR THERAPY



Multi-planar reconstructions

Curved MPR




# Ideal anatomy








# Ideal anatomy

**MEET** 2015  
MULTIDISCIPLINARY EUROPEAN  
ENDOVASCULAR THERAPY



# Challenging access


## Pushing forward the endovascular limits



# Large thoracic sheaths


MEET 2015  
MULTIDISCIPLINARY EUROPEAN  
ENDOVASCULAR THERAPY

- ① Iliac dissection
- ② Iliac rupture
- ③ Iliac stripping



# Pushing the endovascular limits

**MEET** 2015  
MULTIDISCIPLINARY EUROPEAN  
ENDOASCULAR THERAPY





Iliac Stripping



“P.Valdoni” Department of Surgery – Sapienza University of Rome

# Pushing the endovascular limits

MEET 2015  
MULTIDISCIPLINARY EUROPEAN  
ENDOVASCULAR THERAPY



# Background

TEVAR is associated with access and **device delivery challenges** and alternative access techniques can be used to deliver the stent graft with TEVAR when a standard transfemoral access is not feasible



# Anatomic factor severity score

1064 Chaikof et al

JOURNAL OF VASCULAR SURGERY  
May 2002

**Table III.** Definition, grading, and categorization of an initial morphologic state

| Attribute                         | Absent = 0                          | Mild = 1   | Moderate = 2   | Severe = 3  |
|-----------------------------------|-------------------------------------|--|--|---|
| <b>Aortic neck</b>                |                                     |  |  |   |
| Length (L)                        | $L > 25$ mm                         | $15 < L < 25$ mm   | $10 < L < 15$ mm   | $L < 10$ mm   |
| Diameter (d)                      | $d < 24$ mm                         | $24 < d < 26$ mm   | $26 < d < 28$ mm   | $d > 28$ mm   |
| Angle                             | $> 150^\circ$                       | $150^\circ < \text{angle} < 135^\circ$                               | $135^\circ < \text{angle} < 120^\circ$                                       | $\text{Angle} < 120^\circ$  |
| Calcification/thrombus            | $< 25\%$                            | 25-50%   | $> 50\%$   | -   |
| <b>Aortic aneurysm</b>            |                                     |  |  |   |
| Angulation and tortuosity         |                                     |  |  |   |
| Aortic tortuosity index (T)       | $T < 1.05$                          | $1.05 < T < 1.15$  | $1.15 < T < 1.2$   | $T > 1.2$   |
| Aortic angle ( $\Phi$ )           | $160^\circ$ to $180^\circ$          | $140^\circ$ to $159^\circ$   | $120^\circ$ to $139^\circ$   | $< 120^\circ$   |
| Thrombus                          | 0                                   | $< 25\%$   | 25%-50%  | $> 50\%$  |
| Aortic branch vessels             | No vessels                          | 1 lumbar/IMA   | 2 vessels<br>$d < 4$ mm  | 2 vessels<br>IMA $d > 4$ mm   |
| <b>Pelvic perfusion</b>           | Patent bilateral IIA                | Single IIA occlusion   | Single IIA occlusion<br>Contralateral IIA $> 50\%$<br>stenosis               | Bilateral IIA occlusion   |
| <b>Iliac artery</b>               |                                     |  |  |   |
| Calcification                     | None                                | $< 25\%$ vessel length   | 25%-50% vessel length  | $> 50\%$ vessel length  |
| Diameter/occlusive disease        | $d > 10$ mm<br>No occlusive disease | $8 < d < 10$ mm<br>No stenosis $< 7$ mm<br>diameter or $> 3$ cm long | $7 < d < 8$ mm<br>Focal stenosis $< 7$ mm<br>diameter and $< 3$ cm in length | $d < 7$ mm<br>Stenosis $< 7$ mm diameter<br>and $> 3$ cm in length<br>More than one focal<br>stenosis $< 7$ mm diameter |
| <b>Angulation and tortuosity</b>  |                                     |  |  |   |
| Iliac tortuosity index ( $\tau$ ) | $\tau < 1.25$                       | $1.25 < \tau < 1.5$  | $1.5 < \tau < 1.6$   | $\tau > 1.6$  |
| Iliac angle ( $\phi$ )            | $160^\circ$ to $180^\circ$          | $121^\circ$ to $159^\circ$   | $90^\circ$ to $120^\circ$  | $< 90^\circ$  |
| <b>Iliac artery sealing zone</b>  |                                     |  |  |   |
| Length (L)                        | $L > 30$ mm                         | $20 < L < 30$ mm   | $10 < L < 20$ mm   | $L < 10$ mm   |
| Diameter (d)                      | $d < 12.5$ mm                       | $12.5 < d < 14.5$ mm   | $14.5 < d < 17$ mm   | $d > 17$ mm   |

IIA, Internal iliac artery; IMA, inferior mesenteric artery.

Chaikof E.L., et al. J Vasc Surg 2002



# Anatomic factor severity score

|  |  |  |   |  |
|--|--|--|---|--|
| Iliac artery<br>Calcification<br>Diameter/occlusive<br>disease | None<br>d > 10 mm<br>No occlusive disease  | <25% vessel length<br>8 < d < 10 mm<br>No stenosis <7 mm<br>diameter or >3 cm long | 25%-50% vessel length<br>7 < d < 8 mm<br>Focal stenosis <7 mm<br>diameter and <3 cm in length | >50% vessel length<br>d < 7 mm<br>Stenosis < 7 mm diameter<br>and >3 cm in length<br>More than one focal<br>stenosis < 7 mm diameter |
|  | Angulation and tortuosity<br>Iliac tortuosity index ( $\tau$ )<br>Iliac angle ( $\phi$ ) | $\tau < 1.25$<br>160° to 180°  | 1.25 < $\tau < 1.5$<br>121° to 159°   | 1.5 < $\tau < 1.6$<br>90° to 120°  |

## Subscore grading for access failure

|                           |     |                                   |               |  |
|---------------------------|-----|-----------------------------------|---------------|--|
| Calcification             | 0-3 | } 0-15 one side<br>0-30 bilateral | → /5<br>→ /10 | Risk score:<br>0 - none<br>1 - Low<br>2 - Moderate<br>3 - Severe |
| Diameter                  | 0-3 |                                   |               |  |
| Occlusive disease         | 0-3 |                                   |               |  |
| Iliac tortuosity<br>index | 0-3 |                                   |               |  |
| Iliac angle               | 0-3 |                                   |               |  |



Chaikof E.L., et al. J Vasc Surg 2002





# Routine Access


Preoperative DUS measures  
Common femoral a.  
(narrowest diam.)



# Preop. Planning: DUS

Common femoral artery evaluation


- ✓ Vessel size
- ✓ Calcification
- ✓ Associated pathology



# Preop. Planning


Improved evaluation with post-processing

- ✓ Vessel size
- ✓ Tortuosity
- ✓ Calcification
- ✓ Associated pathology




# Common femoral surgical access

- ✓ Direct view of the artery
- ✓ Choose the best puncture site
- ✓ Hand-control of artery during pushing
- ✓ Safe access below the ligament



# Low profile devices



From TEVAR to aortic valve



# Iliac access

Direct puncture



No conduit





# Iliac access

Direct puncture

No conduit





# Aortic access






# Conduit access



# Open Conduit

**MEET** 2015  
MULTIDISCIPLINARY EUROPEAN  
ENDOVASCULAR THERAPY




**General anesthesia**  
**Retroperitoneal access**

**Hypogastric preservation**



# Endoconduit

MEET 2015  
MULTIDISCIPLINARY EUROPEAN  
ENDOVASCULAR THERAPY



Risk of hypogastric  
coveradge

Less complications and  
infection?



# Surgical Conduits

## Iliac Conduits for Endovascular Repair of Aortic Pathologies CME

N. Tsilimparis<sup>a</sup>, A. Dayama<sup>b</sup>, S. Perez<sup>b</sup>, J.J. Ricotta, II<sup>c,\*</sup>

<sup>a</sup>Department of Vascular Medicine - Vascular Surgery, Heart and Vascular Center, Hamburg, Germany  
<sup>b</sup>Department of Surgery, Emory University School of Medicine, Atlanta, USA  
<sup>c</sup>Department of Vascular Surgery and Endovascular Therapy, Northside Heart and Vascular Institute, 980 Johnson Ferry Road NE, Suite 1040, Atlanta, GA 30342, USA

### WHAT THIS PAPER ADDS

Retroperitoneal conduit to establish access in cases of small-diameter or tortuous iliac vessels is an established practice that makes endovascular repair possible. Although use of conduits should be liberal to minimize access site complications, data regarding the outcome after use of conduits is limited. The present paper presents for the first time data from a large cohort of patients using a national registry, thus reflecting real-world data and not data captured from use of devices within clinical trials.

**Objectives:** Challenging iliac access during thoracic endovascular aortic repair (TEVAR) is associated with a higher risk of access site complications such as injury or rupture of the iliac vessels. As a result, the use of iliac conduits is frequently used to facilitate access during TEVAR. This report evaluates the effect of iliac conduits on TEVAR outcomes.

**Methods:** The 2005–2010 American College of Surgeons Surgical Quality Improvement Program database was queried to identify vascular patients undergoing elective TEVAR. Patients without conduit (Group A) were compared to patients who underwent TEVAR with conduit (Group B).

**Results:** We identified 1037 patients (90%) in Group A (69 ± 12.7 years, 42% female) and 117 patients (10%) in Group B (70 ± 12.6 years, 68% female). Women received conduits more often than men (Male: 5.8%, Female: 15.7%,  $p < 0.001$ ). There was no significant difference in the rate of non-surgical (A: 19%, B: 25%,  $p = 0.121$ ), pulmonary (A: 11%, B: 16%,  $p = 0.115$ ), renal (A: 3.1%, B: 1.7%,  $p = 0.4$ ) and cardiovascular complications (A: 8%, B: 12%,  $p = 0.143$ ) between groups. However, any complication (A: 24%, B: 33%,  $p = 0.025$ ), surgical complications (A: 10%, B: 16%,  $p = 0.035$ ) and mortality (A: 4.5%, B: 12%,  $p = 0.001$ ) were significantly higher in Group B. In multivariate analysis, use of conduit was associated with a 3.8 times higher risk of death compared with no conduit after controlling for confounders. Length of in-hospital stay was similar for both groups (A: 6.6 ± 8.8, B: 7.6 ± 8 days,  $p = 0.247$ ). The use of conduits had a declining rate over time from 17.9% in 2006 down to 6.5% in 2010.

**Conclusions:** Female patients more frequently require iliac conduits during TEVAR compared to men. Conduits were associated with a higher rate of surgical complications and mortality. The incidence of conduit use has decreased threefold in the last five years. Safer access for TEVAR by use of a conduit should not be abandoned based on these results, but there should be a heightened awareness for the higher rate of mortality in these patients.

© 2013 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.  
Article history: Received 11 August 2012, Accepted 26 January 2013, Available online 1 March 2013

**Keywords:** Aortic aneurysm, Endovascular repair, TEVAR, Conduit, Thoracic

### INTRODUCTION

Thoracic endovascular aortic repair (TEVAR) has emerged as an important treatment option for several thoracic aortic pathologies providing a significantly lower perioperative morbidity and mortality especially in high-risk patients.<sup>1–4</sup> Despite the evolution of TEVAR since its FDA approval in

2005, achieving safe and adequate access for stent graft introduction remains a critical intraoperative issue. Trans-femoral route for device delivery remains the conventional procedure with feasibility in 70% of cases<sup>5,6</sup> but in a significant number of patients, occlusive iliac disease, iliac tortuosity and small vessel caliber precludes trans-femoral approach. This issue is most commonly addressed through the use of a retroperitoneal iliac conduit. In the multicenter TAG thoracic endoprosthesis (W. L. Gore and Assoc, Flagstaff, Ariz) trial and in an international survey of physicians performing TEVAR, conduits were needed because of access-related issues in 15% of patients.<sup>7,8</sup> Conduit or bypass for vascular access has become part of the standard procedure and serves significantly to expand the subset of patients who undergo TEVAR.

DOI of original article: <http://dx.doi.org/10.1016/j.ejvs.2012.12.016>  
CME To access continuing medical education questions on this paper, please go to [www.vascular-education.com](http://www.vascular-education.com) and click on 'CME'.  
\* Corresponding author. Tel.: +1 770 292 3490.  
E-mail address: [Joseph.Ricotta@northside.com](mailto:Joseph.Ricotta@northside.com) (J.J. Ricotta).  
1078-5884/\$ – see front matter © 2013 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.  
<http://dx.doi.org/10.1016/j.ejvs.2013.01.037>

Conduit were associated with a higher rate of surgical complications and mortality. Safer access for TEVAR by use of a conduit should not be abandoned based on these results, but there should be a heightened awareness for the higher rate of mortality in these patients.



# Surgical vs Endoconduit

MEET 2015  
MULTIDISCIPLINARY EUROPEAN  
ENDOVASCULAR THERAPY

From the Society for Clinical Vascular Surgery

## Alternative access techniques with thoracic endovascular aortic repair, open iliac conduit versus endoconduit technique

Guido H. W. van Bogenrijn, MD,<sup>a</sup> David M. Williams, MD,<sup>b</sup> Jonathan L. Eliason, MD,<sup>c</sup> Narasimham L. Dasika, MD,<sup>b</sup> G. Michael Deeb, MD,<sup>a</sup> and Himanshu J. Patel, MD,<sup>a</sup> Ann Arbor, Mich

**Background:** Iliac artery endoconduits (ECs) have emerged as important alternatives to retroperitoneal open iliac conduits (ROICs) to aid in transfemoral delivery for thoracic endovascular aortic repair (TEVAR). We present, to our knowledge, the first comparative analysis between these alternative approaches.

**Methods:** All patients undergoing TEVAR with either ROIC (n = 23) or internal EC (n = 16) were identified. The mean age of the cohort was 72.4 ± 11.5 years (82.1% female). Device delivery was accomplished in 100% of cases. The primary outcome was the presence of iliofemoral complications, which was defined as (1) the inability to successfully deliver the device into the aorta via the ROIC or EC approach; (2) rupture, dissection, or thrombosis of the ipsilateral iliac or femoral artery; and/or (3) retroperitoneal hematoma requiring exploration and evacuation. Secondary outcomes were 30-day mortality and rates of limb loss, claudication, or revascularization.

**Results:** At a median follow-up of 10.1 months, the incidence of iliofemoral complications was less for the EC approach compared with the ROIC technique (12.5% vs 26.1%; P = .301). No patients sustained limb loss. Revascularization was performed in two patients after ROIC. Lower extremity claudication occurred in one patient after EC. Early mortality was seen in one patient who underwent EC. Two-year Kaplan-Meier survival for the entire cohort was 74.4%, and did not differ between groups (ROIC, 78.3% vs EC, 68.8%; P = .350). Two-year Kaplan-Meier freedom from limb loss, dissection, or revascularization did not differ between the two approaches (ROIC, 91.3% vs EC, 93.8%; P = .961). **Conclusions:** Results of this early comparative evaluation of alternative access routes for TEVAR suggest that an EC approach is safe, effective, and associated with low rates of early mortality and late iliofemoral complications. In selected patients, the EC may be considered an appropriate delivery route for transfemoral TEVAR. (J Vasc Surg 2014;60:1168-76.)

Endovascular techniques, such as thoracic endovascular aortic repair (TEVAR) and transcatheter aortic valve replacement have been successfully introduced as less invasive treatment modalities for thoracic aortic pathology.<sup>1-4</sup> Nevertheless, TEVAR is associated with access and device delivery challenges and alternative access techniques can be used to deliver the stent graft with TEVAR when a standard transfemoral access is not feasible. We have previously suggested that iliofemoral complications in patients who undergo transfemoral TEVAR are predicted by the difference between the average iliac diameter and sheath size, increased iliac artery morphology score, and preoperative ankle-brachial index (ABI).<sup>5</sup> Furthermore, iliofemoral complications reduced late survival rates primarily because of high mortality rates within the first year.<sup>5</sup> To reduce

iliofemoral complications, various approaches have been performed to avoid arterial access limitations during TEVAR, with most requiring retroperitoneal access or aggressive angioplasty, potentially leading to life-threatening complications.<sup>6-9</sup>

When TEVAR candidates have unfavorable iliac artery anatomy, including a small-caliber iliac artery, iliac artery tortuosity, or occlusive disease, in combination with the need for large-diameter delivery sheaths, the retroperitoneal open iliac conduit (ROIC) has been considered the most appropriate route for stent graft delivery.<sup>10</sup> This approach requires either intra-abdominal or retroperitoneal access vessel exposure, resulting in a more complex surgical plan and extended postoperative recovery. More recently, the internal endoconduit (EC) approach has been introduced as an alternative for stent graft delivery, and can be performed using a standard femoral approach.<sup>11</sup> To explore the initial applicability of these techniques in patients at high risk for iliofemoral complications, we present an early comparative analysis between ROIC and EC as alternative stent graft delivery approaches with TEVAR.

### METHODS

This single-center retrospective study was approved by the Institutional Review Board of the University of Michigan Medical School (HUM00053164; informed consent waived). All patients undergoing TEVAR from December 1993 to February 2014 were reviewed for study

From the Departments of Cardiac Surgery,<sup>a</sup> Radiology<sup>b</sup> and Vascular Surgery,<sup>c</sup> University of Michigan Frankel Cardiovascular Center.

Author conflict of interest: none.

Presented at the Forty-second Annual Symposium of the Society for Clinical Vascular Surgery, Carlsbad, Calif, March 18-22, 2014.

Reprint requests: Himanshu J. Patel, MD, Associate Professor of Cardiac Surgery, University of Michigan Hospitals, Department of Cardiac Surgery, 1500 E Medical Center Dr, 5144 Cardiovascular Center/SPC 5864, Ann Arbor, MI 48109-5864 (e-mail: hpatel@med.umich.edu).

The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.

0741-5214/\$36.00  
Copyright © 2014 by the Society for Vascular Surgery.  
<http://dx.doi.org/10.1016/j.jvs.2014.05.008>

**Conclusions:** This early comparative evaluation of alternative access routes for TEVAR suggests that the EC approach described is safe, effective, and associated with low rates of early mortality and late iliofemoral complications.

"P.Valdoni" Department of Surgery – Sapienza University of Rome



# Conclusions

- ✓ Endoconduit reduce total operation time
- ✓ More confort
- ✓ Less recovery time
- ✓ No general anesthesia
- ✓ Avoid infection



# Thank you

**MEET** 2015  
MULTIDISCIPLINARY EUROPEAN  
ENDOVASCULAR THERAPY



Francesco Setacci, MD  
francescosetacci@gmail.com



"P.Valdoni" Department of Surgery – Sapienza University of Rome